An Indigenous Workflow for Generating CD19 CAR-T Cells.

Area of Science:

• Immunology
• Cell and Gene Therapy
• Oncology

Background:

• FDA-approved CD19 CAR T-cell therapy shows promise for B-cell malignancies but faces challenges.
• Limitations include immune effector cell-associated neurotoxicity syndrome (ICANS), hematotoxicity (ICAHTs), high costs, and complex logistics.
• These factors hinder widespread patient access to CAR T-cell therapy.

Purpose of the Study:

• To develop a safe, cost-effective, and streamlined indigenous workflow for CAR T-cell generation and characterization.
• To optimize a method for producing CD19 CAR T cells from peripheral blood T cells of healthy donors.
• To facilitate preclinical and clinical research by providing a reproducible protocol.

Main Methods:

• Optimization of a lentiviral transduction protocol for T-cell expansion and gene modification.
• Development of an indigenous workflow for generating CD19 CAR T cells.
• Characterization of the generated CD19 CAR T cells for immunological assessment and downstream applications.

Main Results:

• An optimized method for developing CD19 CAR T cells from healthy donor peripheral blood T cells has been established.
• The protocol provides a streamlined and cost-effective approach to CAR T-cell generation.
• The generated cells are suitable for immunological studies and potential downstream applications.

Conclusions:

• The developed indigenous protocol offers a viable solution for producing CD19 CAR T cells.
• This workflow addresses the accessibility issues associated with current CAR T-cell therapies.
• The protocol supports further research into CAR T-cell immunology and clinical applications.